-
-
-
-
-
-
-
Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Ad
-
-
-
-
-
-
-
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
-
-
-
-
-
-
-
Jaguar Health (JAGX) Granted Orphan Drug Designation for Crofelemer to Napo EU by the European Medicines Agency
-
-
-
-
-
-
-
Form S-1 Jaguar Health, Inc.
-
-
-
-
-
-
-
Jaguar Health Announces Pricing of $14.4 Million Underwritten Public Offering
-
-
-
-
-
-
-
Jaguar Health (JAGX) Prices 15M Share Common Public Offering at $0.60/Sh
-
-
-
-
-
-
-
Form S-1/A Jaguar Animal Health,
-
67,416 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

